BR9815442A - Liberação terapêutica dirigida de compostos de vitamina d - Google Patents

Liberação terapêutica dirigida de compostos de vitamina d

Info

Publication number
BR9815442A
BR9815442A BR9815442-7A BR9815442A BR9815442A BR 9815442 A BR9815442 A BR 9815442A BR 9815442 A BR9815442 A BR 9815442A BR 9815442 A BR9815442 A BR 9815442A
Authority
BR
Brazil
Prior art keywords
vitamin
conjugate
compounds
targeted therapeutic
therapeutic release
Prior art date
Application number
BR9815442-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard B Mazess
Charles W Bishop
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of BR9815442A publication Critical patent/BR9815442A/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR9815442-7A 1997-02-13 1998-02-13 Liberação terapêutica dirigida de compostos de vitamina d BR9815442A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3836497P 1997-02-13 1997-02-13
PCT/US1998/002899 WO1998035704A1 (en) 1997-02-13 1998-02-13 Targeted therapeutic delivery of vitamin d compounds

Publications (1)

Publication Number Publication Date
BR9815442A true BR9815442A (pt) 2001-08-21

Family

ID=21899512

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815442-7A BR9815442A (pt) 1997-02-13 1998-02-13 Liberação terapêutica dirigida de compostos de vitamina d

Country Status (12)

Country Link
US (1) US6929797B2 (https=)
EP (1) EP0981376A1 (https=)
JP (1) JP2001511811A (https=)
KR (1) KR20000071039A (https=)
CN (1) CN1254293A (https=)
AU (1) AU750451B2 (https=)
BR (1) BR9815442A (https=)
CA (1) CA2279590A1 (https=)
HU (1) HUP0002454A2 (https=)
NZ (1) NZ336924A (https=)
PL (1) PL336231A1 (https=)
WO (1) WO1998035704A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2413499A (en) 1997-12-17 1999-07-05 Schering Aktiengesellschaft Vitamin d derivatives with phosphorous atoms in the side chains
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US7598246B2 (en) 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
EP1146050B1 (en) 1999-01-20 2009-12-09 Takara Bio Inc. 4-Substituted-3,6-anhydro-galactose derivatives and their pharmaceutical use
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
EP1383510B1 (en) * 2001-04-10 2012-10-17 MBC Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
DE10156596A1 (de) * 2001-11-13 2003-05-28 Schering Ag Vitamin D-Derivate mit Acyloxygruppen in der Seitenkette, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
MX2007006261A (es) * 2004-11-22 2007-07-10 Wisconsin Alumni Res Found Analogos de 17,20(z)-deshidro vitamina d y sus usos.
US20100144671A1 (en) * 2005-03-04 2010-06-10 Women And Infants Hospital Of Ri, Inc. Compositions and Methods for Cancer Treatment
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2008012912A (es) * 2006-04-06 2008-11-26 Wisconsin Alumni Res Found Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos.
WO2009086436A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
US7718638B2 (en) * 2007-12-28 2010-05-18 Wisconsin Alumni Research Foundation (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
US8772235B2 (en) 2009-10-14 2014-07-08 The Governors Of The University Of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
CA2843885C (en) * 2011-08-01 2020-03-10 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CN108524919A (zh) * 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US9244083B2 (en) 2012-11-30 2016-01-26 Siemens Healthcare Diagnostics Inc. Compositions and methods for detecting vitamin D
US9618523B2 (en) 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN105381470B (zh) * 2015-11-27 2018-11-02 广东医科大学 一种改性染料木素及其应用
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗b7−h3抗体及び抗体薬物コンジュゲート
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CN111440105B (zh) * 2020-04-01 2022-05-17 南通华山药业有限公司 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN116082536B (zh) * 2023-02-16 2024-04-26 广州汇元医药科技有限公司 具有骨靶向功能的聚合物及其制备方法和用途、纳米载体及其制备方法
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2383446A (en) 1941-06-04 1945-08-28 Du Pont Antirachitic materials and processes for their production
US3697559A (en) 1971-02-25 1972-10-10 Wisconsin Alumni Res Found 1,25-dihydroxycholecalciferol
US3741996A (en) 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US3907843A (en) 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
NL188286C (nl) 1978-01-16 1992-05-18 Wisconsin Alumni Res Found Werkwijze voor het bereiden van een 1alfa-hydroxyvitamine d verbinding.
US4260549A (en) 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4160803A (en) 1978-03-23 1979-07-10 Corning Glass Works Self packaged test kit
US4225596A (en) 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4362710A (en) 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4292250A (en) * 1980-11-17 1981-09-29 Wisconsin Alumni Research Foundation Vitamin D derivatives
JPS57149224A (en) 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4508651A (en) 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
DE3448360C2 (https=) 1983-05-09 1991-10-02 Wisconsin Alumni Res Found
US4689180A (en) 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4588716A (en) 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4554106A (en) 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
GR861167B (en) 1985-05-02 1986-09-30 Research Corp Bone targeted inhibitors of carbonic anhydrase
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4902481A (en) 1987-12-11 1990-02-20 Millipore Corporation Multi-well filtration test apparatus
US5232836A (en) * 1988-05-04 1993-08-03 Ire-Medgenix S.A. Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JPH0778024B2 (ja) 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5372996A (en) 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
JP2645130B2 (ja) 1989-03-31 1997-08-25 日清製粉株式会社 ステロイド誘導体
GB2229921B (en) 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
US5219528A (en) 1989-07-28 1993-06-15 Pierce Chemical Company Apparatus for rapid immunoassays
WO1993007883A1 (en) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5141719A (en) 1990-07-18 1992-08-25 Bio-Rad Laboratories, Inc. Multi-sample filtration plate assembly
WO1992005130A1 (en) 1990-09-21 1992-04-02 Lunar Corporation NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
DE69233074T2 (de) 1991-01-08 2004-03-18 Bone Care International Inc., Madison Verfahren zur Herstellung von 1-alpha-24-dihydroxy-Vitamin D2
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
AU1424492A (en) * 1991-02-20 1992-09-15 Christopher Capelli Non-protein intracellular receptor binding conjugates and a method of use thereof
DK0503630T3 (da) 1991-03-13 1996-01-29 Kuraray Co Cyclohexantriolderivater
US5264184A (en) 1991-03-19 1993-11-23 Minnesota Mining And Manufacturing Company Device and a method for separating liquid samples
US5417923A (en) 1991-04-24 1995-05-23 Pfizer Inc. Assay tray assembly
JPH07500315A (ja) 1991-05-10 1995-01-12 セルトリックス ファーマシューティカルズ,インコーポレイテッド 骨成長因子の標的送達
CA2109958C (en) * 1991-05-28 1997-06-10 Mark Benson Andon Calcium, trace mineral, vitamin d and drug therapy combinations
DK0521550T3 (da) 1991-07-05 1996-11-04 Duphar Int Res Vitamin D forbindelse, fremgangsmåde til fremstilling af denne forbindelse og mellemprodukt derfor
US5205989A (en) 1991-09-18 1993-04-27 Minnesota Mining And Manufacturing Company Multi-well filtration apparatus
EP0631500B1 (en) 1992-01-29 1998-04-22 Bone Care International, Inc. 1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
JPH05320127A (ja) 1992-03-27 1993-12-03 Nisshin Flour Milling Co Ltd 活性型ビタミンd誘導体
EP0562497A1 (en) 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
JP2520074B2 (ja) * 1992-06-11 1996-07-31 呉羽化学工業株式会社 新規なエストラジオ―ル誘導体−クロラムブチル結合体、その製造方法、及び医薬製剤
DK0600079T3 (da) 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5350745A (en) 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
US5763429A (en) 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
ES2120122T3 (es) 1994-01-20 1998-10-16 Duphar Int Res Compuestos de vitamina d y metodo de preparar estos compuestos.
US5597575A (en) 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US5739271A (en) 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5691328A (en) * 1996-02-02 1997-11-25 Clarion Pharmaceuticals Inc. Phosphoethanolamine conjugates of vitamin D compounds
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders

Also Published As

Publication number Publication date
KR20000071039A (ko) 2000-11-25
JP2001511811A (ja) 2001-08-14
WO1998035704A1 (en) 1998-08-20
AU750451B2 (en) 2002-07-18
US6929797B2 (en) 2005-08-16
US20020136731A1 (en) 2002-09-26
PL336231A1 (en) 2000-06-19
AU6326798A (en) 1998-09-08
EP0981376A1 (en) 2000-03-01
CA2279590A1 (en) 1998-08-20
HUP0002454A2 (hu) 2000-12-28
NZ336924A (en) 2001-06-29
CN1254293A (zh) 2000-05-24

Similar Documents

Publication Publication Date Title
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BR0316906A (pt) administração do capsaicinoides
BR9906581A (pt) Processo para administração de taxano encapsulado em lipossomos
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BR0315580A (pt) Derivados de metileno uréia
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
BR9912179A (pt) Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão
BRPI0114344B8 (pt) composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O ,6O ,7O, 8O E 9O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/54 (2017.0